{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:39:15Z","timestamp":1789915155315,"version":"4.0.1"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,4]]},"abstract":"<jats:p> PURPOSE: Prognostic factors were studied in children older than 1 year who were treated with chemotherapy for extracranial localized malignant non seminomatous germ cell tumors. <\/jats:p><jats:p> PATIENTS AND METHODS: Data from two consecutive protocols were pooled. The TGM 85 (1985-1989) protocol consisted of alternating courses of cyclophosphamide, dactinomycin and vinblastine, bleomycin, and cisplatin at a dose of 100 mg\/m<jats:sup>2<\/jats:sup> per course. The TGM 90 (1990-1994) protocol was initiated with carboplatin 400 mg\/m<jats:sup>2<\/jats:sup> substituted for cisplatin as the only modification to the previous protocol. <\/jats:p><jats:p> RESULTS: We examined alpha-fetoprotein (AFP) levels, disease stage, and primary site and identified three prognostic groups. Patients with a poor prognosis had either an AFP level \u2265 10,000 ng\/mL or stage III disease and a sacrococcygeal or mediastinal primary site; such patients represented 46% of the patient population and experienced a 43% 3-year failure-free survival rate and a 77% overall survival rate. Patients with a good prognosis had an AFP level less than 10,000 ng\/mL, stage I or II disease, and a testicular, ovarian, perineal, or retroperitoneal primary site; such patients represented 22% of the patient population and experienced no treatment failures. The other patients were classified in the intermediate prognosis group and represented 37% of the patient population, with an 81% 3-year failure-free survival rate and a 92% overall survival rate. <\/jats:p><jats:p> CONCLUSION: Initial AFP level, disease stage, and primary site are the most important prognostic factors in this analysis. Prognostic models for pediatric germ cell tumors should allow the stratification of patients for a risk-adapted approach to treatment. <\/jats:p>","DOI":"10.1200\/jco.1999.17.4.1212","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:21:13Z","timestamp":1487917273000},"page":"1212-1212","source":"Crossref","is-referenced-by-count":109,"title":["Prognostic Factors in Children With Localized Malignant Nonseminomatous Germ Cell Tumors"],"prefix":"10.1200","volume":"17","author":[{"given":"M. C.","family":"Baranzelli","sequence":"first","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kramar","sequence":"additional","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bouffet","sequence":"additional","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Quintana","sequence":"additional","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rubie","sequence":"additional","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Edan","sequence":"additional","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Patte","sequence":"additional","affiliation":[{"name":"From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-1212","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(75)80484-7"},{"key":"R2-1212","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197808)42:2<390::AID-CNCR2820420203>3.0.CO;2-Z"},{"key":"R3-1212","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850715)56:2<243::AID-CNCR2820560206>3.0.CO;2-T"},{"key":"R4-1212","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-3-293"},{"key":"R5-1212","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900501)63:9<1657::AID-CNCR2820630902>3.0.CO;2-8"},{"key":"R6-1212","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921115)70:10<2568::AID-CNCR2820701028>3.0.CO;2-1"},{"key":"R7-1212","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190405"},{"key":"R8-1212","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.10.1782"},{"key":"R9-1212","doi-asserted-by":"crossref","unstructured":"Flamant  F,  Baranzelli  MC,  Kalifa  C, et al: Treatment of malignant germinal cell tumors in children: Experience of the Institut Gustave Roussy and the French Society of Pediatric Oncology.  Oncol Hematol 10:99,1990-110,","DOI":"10.1016\/1040-8428(90)90002-A"},{"key":"R10-1212","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1025312"},{"key":"R11-1212","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811015)48:8<1890::AID-CNCR2820480830>3.0.CO;2-D"},{"key":"R12-1212","doi-asserted-by":"crossref","unstructured":"Medical Research Council Working Party on Testicular Tumors: Prognostic factors in advanced nonseminomatous germ-cell testicular tumors: Results of a muticenter study.  Lancet 1:8,1985-11,","DOI":"10.1016\/S0140-6736(85)90963-8"},{"key":"R13-1212","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.3.400"},{"key":"R14-1212","unstructured":"Stoter  G,  Sylvester  R,  Sleijfer  D: Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from a European Organization for Research and Treatment of Cancer multi-institutional phase III study.  Cancer Res 47:2714,1987-2718,"},{"key":"R15-1212","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.85"},{"key":"R16-1212","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"R17-1212","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.707"},{"key":"R18-1212","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950210602"},{"key":"R19-1212","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R21-1212","doi-asserted-by":"crossref","unstructured":"Cox  DR: Regression models and life tables (with discussion).  J R Stat Soc (Series B) 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R22-1212","unstructured":"Flamant  F,  Hartmann  O,  Kalifa  C, et al: Review of a series of 82 non-seminomatous malignant germ cell tumours (nsGCT) treated at the same center between 1978 and 1984.  Med Pediatr Oncol 15:307,1987-311,"},{"key":"R23-1212","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1025232"},{"key":"R24-1212","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199511000-00007"},{"key":"R25-1212","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<217::AID-MPO3>3.0.CO;2-J"},{"key":"R26-1212","unstructured":"Patte  C,  Baranzelli  MC,  Quintana  E, et al: Carboplatin is less efficient Cis-platinum in chilhood non metastatic non seminomatous germ cell tumor treated in SFOP TGM 85 and TGM 90 protocols.  Proc Am Soc Clin Oncol 14:438,1995,  (abstr 1396)"},{"key":"R27-1212","doi-asserted-by":"crossref","unstructured":"Gobel  U,  Haas  RJ,  Calaminus  G, et al: Treatment of germ cell tumors in children: Results of European trials for testicular and non-testicular primary sites.  Oncol Hematol 10:89,1990-98,","DOI":"10.1016\/1040-8428(90)90001-9"},{"key":"R28-1212","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861215)58:12<2579::AID-CNCR2820581204>3.0.CO;2-V"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.4.1212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:31:58Z","timestamp":1653514318000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.4.1212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["10.1200\/JCO.1999.17.4.1212"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.4.1212","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}